Emcure Pharmaceuticals inches up on getting nod to incorporate wholly-owned subsidiary
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Emcure Pharmaceuticals is currently trading at Rs. 1421.30, up by 0.65 points or 0.05% from its previous closing of Rs. 1420.65 on the BSE.
The scrip opened at Rs. 1439.00 and has touched a high and low of Rs. 1453.40 and Rs. 1419.90 respectively. So far 1828 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1461.95 on 11-Sep-2024 and a 52 week low of Rs. 1226.50 on 13-Aug-2024.
Last one week high and low of the scrip stood at Rs. 1461.95 and Rs. 1375.30 respectively. The current market cap of the company is Rs. 26876.55 crore.
The promoters holding in the company stood at 48.01%, while Institutions and Non-Institutions held 13.09% and 38.90% respectively.
Emcure Pharmaceuticals has received approval for the incorporation of a wholly-owned subsidiary (WOS) by the name ‘Emcutix Biopharmaceuticals’ in Pune, Maharashtra, India. WoS is being incorporated to manufacture, promote, sale and distribute pharmaceuticals and other related product(s). A Committee of the Board of Directors of the Company in their meeting held on September 13, 2024, has inter-alia approved the same.
Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.
